A comparison of roxatidine acetate 150 mg once daily and 75 mg twice daily in gastric ulcer healing.

Abstract

In 363 outpatients with endoscopically confirmed gastric ulcers the efficacy and safety of roxatidine acetate 150 mg at night was compared to 75 mg twice daily. After 8 weeks' treatment substantial reductions in gastric ulcer diameter were obtained in addition to healing rates of 83.7 and 86% for the twice daily and night-time dosing, respectively. Daily reductions in day and night-time epigastric pain were obtained with no significant differences between treatment groups for pain scores or antacid tablet consumption. Furthermore, cigarette smoking did not influence the healing rates produced by either treatment schedule. 26 patients reported 32 adverse reactions and 5 patients discontinued treatment because of side effects, although only 1 of these was a severe reaction. The present data suggest that a single night-time dose of roxatidine acetate 150 mg is as safe and effective as the twice daily dose regimen for the management of acute gastric ulceration.

• Authors: W Rösch
• Journal: Drugs (Drugs) Vol. 35 Suppl 3 Pg. 127-33 ( 1988) ISSN: 0012-6667 [Print] New Zealand
• PMID: 2905241 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Histamine H2 Antagonists
• Piperidines
• TZU 0460

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Histamine H2 Antagonists (administration & dosage, adverse effects, therapeutic use)
• Humans
• Male
• Middle Aged
• Piperidines (administration & dosage, adverse effects, therapeutic use)
• Random Allocation
• Stomach Ulcer (drug therapy)
• Time Factors